At various times in my life, as a child and with my own children, I have had the pleasure of tackling new jigsaw puzzles. The difficult ones were those with lots of sky or sea or green grass or trees, and the easier ones had buildings or trains or planes or people or animals. The main reasons for confidence were the knowledge that all the necessary pieces were there, and that, correctly fitted together, they would re-form the picture shown on the outside of the box.
At the moment, mainly as a result of my own foolishness, I am simultaneously writing three chapters for separate books, all of which are due to be submitted by the end of March. They are about the application of new technologies in drug discovery and development, the use of integrated testing strategies in applying new technologies to the toxicity testing of chemicals, and the ethics and regulation of the animal testing of dental implants.
As I sit here, surrounded by textbooks, reports, journal articles, and with a screen full of icons for all the items I have downloaded, I am struck by the conviction that the three topics appear to have one thing in common -tackling them seems to be rather like doing very demanding jigsaw puzzles.
Of course, the second common thread of these three puzzles, which is of particular concern to FRAME, is that they emphasise the need to replace the traditional animal models for testing the efficacy and safety of drugs for clinical use, and for evaluating the toxicity of chemicals and other materials, as a basis for using them as safely as possible in the vast range of products from which we all benefit in one way or another. And, indeed, each topic has its own associated confounding issues related to the use of animal tests.
In drug discovery and development, preclinical testing in animals fails to be a reliable way of predicting either lack of efficacy or unexpected toxicity, and this has resulted in an alarming increase in the withdrawal of drugs at a late stage of development, or even after they have been accepted for use on a population scale. The problem with the evaluation of chemical toxicity is that the EU REACH system has revealed that many more chemicals than had been expected, lack the information needed for what is considered to be an acceptable risk assessment. Also, it is having to be recognised, albeit very reluctantly in some quarters, that two of the main types of animal test, which are very costly and which can cause great suffering to the animals used, namely, reproductive toxicity tests and the rodent bioassay for chemical carcinogens, simply cannot be relied on to identify chemicals likely to have adverse effects during human reproduction or to cause cancer in humans. Dental implants represent an in-between case, as they are deliberately put into the human body, but lack the powerful effects on biological systems that are required of effective drugs.
The ongoing and vast expansion of technological developments is adding to the complexity of the necessary puzzle-solving. There is now an abundance of alternative methods, each of which can add a few more pieces of information to an ever-increasing knowledge base, but few of which can stand alone. These include: ever more-sophisticated in silico models; in vitro systems (involving, for example, cell cocultures; stem cells, multi-organ systems, tissue engineering, dynamic bioreactors, and organ-on-achip systems); physiologically-based pharmacokinetic and toxicokinetic models; and a variety of 'omics' approaches (such as genomics, proteomics, and metabolonomics). Selecting the methods to be used, and deciding how they could be used in manageable and affordable strategies, is a daunting task. There is also the danger of being overwhelmed by the vast volume of information they produce, in collusion with many different computer programs, which threatens to frustrate proper analysis and effective use.
The ways in which the multitude of new pieces of information obtained can be fitted together to form pictures and answers to puzzles, differ fundamentally from the challenges represented by the conventional jigsaw puzzles of the past that I look back on with warmth and great pleasure, such as the one of Pieter Brueghel the Elder's Hunters in the Snow.
As we tackle questions related to the efficacy, toxicity and safety of chemicals, drugs and other chemical products used in all kinds of ways in the complex lives we live in the 21st century, we must realise that, though we have many pieces to try to fit together, we certainly don't have all the pieces we need and we don't know how many pieces are missing. In addition, we must be suspicious that the pieces we do have are not merely the parts of one puzzle, but may be parts of an unknown number of different puzzles. Moreover, we cannot assume that all the pieces are of equal value, as we know that, far from being lifeless equivalents cut from the original picture with a jig-saw to form a conventional jigsaw puzzle, there are, within each piece of information having potential pharmacotoxicological significance, stories and histories, and pluses and minuses, and main streams and blind alleys, and dynamic interactions among them, that are far more profound. Worst of all, we have no picture on a box to guide us -we have to create the eventual picture or pictures ourselves, by using strategies and applying rules which we have to devise and lay down along the way.
How, then, can we proceed? We can make use of the new ways available to us for producing information, for storing information, and for analysing information, by applying integrated strategies which make full, appropriate and combined use of artificial in silico computers and the natural in vivo computers represented by the brains of the scientists involved. I am tempted to say that they must be intelligent strategies, but I don't want to get into discussions about whether the in silico computers can be wise or about the error-prone tendencies of the in vivo ones.
We can also do our best to ensure that what is done is conducted according to the highest ethical standards and by applying procedures which are themselves well-designed, transparent and open to independent scrutiny. These procedures must be applied only within the applicability domains to which they are appropriate -the outcome of a procedure might tell you what it could tell you, but it cannot uncover that which is beyond its capacity to reveal. In addition, outcomes should be expressed according to prediction models -that is, unambiguous algorithms for converting the results into predictions of relevant endpoints of interest or concern (e.g. the potential to cause liver injury in humans). We should also bear in mind that, whatever tests might be performed, and however intelligent the integrated strategies that might be used, the best that can be offered is an expression of probability that a particular event could or would occur. Science cannot offer certainty.
So, how should we approach the solving of these pharmacotoxicological puzzles? We should begin by rejecting Karl Marx's wise generalisation as not pertinent to this particular case, since we know that we do not already have the solutions to the problems. Then, instead of trying to solve puzzles given to us by other people, as when we buy jigsaw puzzles in the toyshop or the stationer's, we should embark on creating the puzzles ourselves, followed by trying to find or produce the pieces to fit together to build the pictures to put on our boxes. Along the way, we must avoid the shotgun approach of mindless, high-throughput screening, and we must never try to reproduce what animal tests of doubtful value would have provided. With all the technology now available to us, we should strive to understand the nature of the puzzles which confront us, and the interactions between the pieces which will help us to achieve our goals of reducing risk and relieving suffering. 
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